Healthspan taxonomy seed — see taxonomy_path
Current stock research snapshot · 7/31/26 26 days old
NVONovo Nordisk
Investment conviction●●○○○2 of 5 · current snapshot
Research target$109.07Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$228.08BSnapshot value · 7/31/26
Novo Nordisk Q2 2026 earnings; semaglutide (Ozempic/Wegovy) ex-US pricing update; amycretin Phase 2 oral obesity data; CagriSema timeline
Thesis breaks if FY2026 sales stay 0% to -6% CER (Ozempic -2%, Rybelsus -9%), CagriSema misses the ~25% bar again, or ZEUS-type failures (ziltivekimab) repeat across the pipeline. (vault 2026-08)
Neutral — Chart +4% with stacked setups; compared favorably to HIMS but no specific contracts. [X search Aug 2026]
Snapshot · 7/31/26🟢 Lean-Bull · 13F 18+/6-×0.5 · short↑0.23
Snapshot · 7/31/26Timestamped research update
Deep research update
436 words · Updated Aug 15, 2026
Research in development: this latest 436-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Novo Nordisk sells GLP-1 receptor agonist therapies for metabolic disease — semaglutide across Ozempic (T2D injectable), Rybelsus (T2D oral), Wegovy injectable (obesity), and Wegovy pill (obesity oral) — plus insulin and rare-disease franchises. The healthspan thesis is that Novo owns the dominant intervention for obesity and type-2 diabetes, the two highest-prevalence metabolic conditions.
H1 2026 net sales DKK 175,311M (+18% CER reported / +2% CER adjusted); Q2 2026 net sales DKK 78,488M; adjusted operating margin 42.5%; H1 free cash flow DKK 55,297M (+44%); FY2025 revenue DKK 309,064M (20-F).
Novo is the bottleneck supplier of the GLP-1 intervention layer. The moat is the multi-ton semaglutide manufacturing base + oral-formulation exclusivity (Wegovy pill = first oral obesity GLP-1). H1 2026 shows the franchise is complete on the build side (capex −15%, FCF +44%) but decelerating on the demand side (adjusted sales +2% CER, FY guide 0 to −6%).
- GLP-1 franchise H1 2026 = DKK 112,193M (Ozempic 59,200 / Rybelsus 9,800 / Wegovy inj 37,719 / Wegovy pill 5,474).
- Ozempic −2% CER and Rybelsus −9% CER H1 — the diabetes GLP-1 base is contracting.
- Wegovy pill: 265,000+ weekly US prescriptions (week ending 2026-07-17); ~2.9M Q2 scripts; self-pay $149–299/month; "strongest-ever GLP-1 volume launch."
- Wegovy 7.2 mg (STEP UP, 20.7% weight loss) and Wegovy pill (OASIS 4, 16.6%) both EMA-approved July 2026.
- CagriSema: REDEFINE 9 (lower dose) completed; high-dose REDEFINE (2.4/7.2 mg) phase 3 initiated — next engine still years out.
- ziltivekimab ZEUS phase 3 failed; monlunabant DKK 4.0B impairment.
Multi-ton semaglutide peptide manufacturing + first/only oral peptide GLP-1 formulations + 60-country Wegovy distribution + clinical-data dose-escalation ladder. The moat is real but the scarcity premium has faded as capacity came online — the value is now brand/clinical/oral exclusivity, not supply scarcity.
- Ozempic/Rybelsus contraction outruns Wegovy pill ramp → franchise revenue shrinks in DKK.
- CagriSema high-dose reads below ~25% weight loss → no next-gen growth engine.
- Oral competition (orforglipron) erodes Wegovy pill's first-mover oral lead.
- US pricing/rebate dynamics (340B, IRA) compress gross margin further.
- What is the US Wegovy pill net-price-per-script after rebates (self-pay list $149–299 is not the realized price)?
- Does CagriSema high-dose (2.4/7.2 mg) reach the ~25% bar in Phase 3, and when?
- Can the obesity franchise (>38% of GLP-1 sales and rising) offset the contracting diabetes base in FY2027?
INTACT (moat intact + capex harvest underway; growth engine downshifted to 0 to −6% adjusted).